151 related articles for article (PubMed ID: 1330598)
1. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability.
Beil W; Staar U; Sewing KF
Eur J Pharmacol; 1992 Aug; 218(2-3):265-71. PubMed ID: 1330598
[TBL] [Abstract][Full Text] [Related]
2. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
3. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
4. Substituted thieno[3,4-d]imidazoles, a novel group of H+/K(+)-ATPase inhibitors. Differentiation of their inhibition characteristics from those of omeprazole.
Beil W; Staar U; Sewing KF
Eur J Pharmacol; 1990 Oct; 187(3):455-67. PubMed ID: 1963594
[TBL] [Abstract][Full Text] [Related]
5. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
Shin JM; Sachs G
Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
[TBL] [Abstract][Full Text] [Related]
6. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
7. [Inhibitory action of E3810 on H+,K(+)-ATPase and gastric acid secretion in vitro].
Fujisaki H; Oketani K; Shibata H; Murakami M; Fujimoto M; Wakabayashi T; Yamatsu I; Takeguchi N
Nihon Yakurigaku Zasshi; 1993 Dec; 102(6):389-97. PubMed ID: 8282270
[TBL] [Abstract][Full Text] [Related]
8. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
Besancon M; Simon A; Sachs G; Shin JM
J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
[TBL] [Abstract][Full Text] [Related]
9. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
10. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
Mattsson JP; Väänänen K; Wallmark B; Lorentzon P
Biochim Biophys Acta; 1991 Jun; 1065(2):261-8. PubMed ID: 1647821
[TBL] [Abstract][Full Text] [Related]
11. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
12. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.
Kromer W; Krüger U; Huber R; Hartmann M; Steinijans VW
Pharmacology; 1998 Feb; 56(2):57-70. PubMed ID: 9494064
[TBL] [Abstract][Full Text] [Related]
13. The site of action of pantoprazole in the gastric H+/K(+)-ATPase.
Shin JM; Besancon M; Simon A; Sachs G
Biochim Biophys Acta; 1993 Jun; 1148(2):223-33. PubMed ID: 8389196
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
[TBL] [Abstract][Full Text] [Related]
15. Studies on the mechanism of action of omeprazole.
Keeling DJ; Fallowfield C; Milliner KJ; Tingley SK; Ife RJ; Underwood AH
Biochem Pharmacol; 1985 Aug; 34(16):2967-73. PubMed ID: 2992525
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Lorentzon P; Bayati A; Lee H; Andersson K
Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
[No Abstract] [Full Text] [Related]
17. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.
Morii M; Takata H; Fujisaki H; Takeguchi N
Biochem Pharmacol; 1990 Feb; 39(4):661-7. PubMed ID: 2154989
[TBL] [Abstract][Full Text] [Related]
18. Restoration of acid secretion following treatment with proton pump inhibitors.
Shin JM; Sachs G
Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
[TBL] [Abstract][Full Text] [Related]
20. (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
Kohl B; Sturm E; Senn-Bilfinger J; Simon WA; Krüger U; Schaefer H; Rainer G; Figala V; Klemm K
J Med Chem; 1992 Mar; 35(6):1049-57. PubMed ID: 1313110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
